But even though BSX stock was trading near at its 52-week high last week, it’s down ~0.96% over the past week. Over the past month, it has risen ~5.3%. Year-to-date, it has reported stellar gains of ~53%.

The one-year stock price return for BSX stands at ~29.8%. As of October 4, its 50-day moving average is $36.48, and its 200-day moving average is $32.31.

Its peers Medtronic (MDT), Edwards Lifesciences (EW), and Abbott Laboratories (ABT) have returned 22.6%, 39%, and 31.6%, respectively, over the past year.

Major events that triggered Boston Scientific’s recent stock performance

On October 2, Morgan Stanley raised its target price for BSX stock. That day, BSX stock was trading at its 52-week high. On September 28, Jefferies raised its target price for BSX stock, and the stock closed up ~0.42% compared to the previous day. On September 24, BSX stock touched its 14-year high at the time, triggered by news of the approval of its Eluvia stent in the United States.

Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!